154.19 USD
+1.71 (+1.12%)
We assign a fundamental rating of 5 out of 10 to ILMN. ILMN was compared to 57 industry peers in the Life Sciences Tools & Services industry. ILMN has an excellent profitability rating, but there are some minor concerns on its financial health. ILMN has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
- In the past year ILMN was profitable.
- In the past year ILMN had a positive cash flow from operations.
- The reported net income has been mixed in the past 5 years: ILMN reported negative net income in multiple years.
- Each year in the past 5 years ILMN had a positive operating cash flow.
1.2 Ratios
- ILMN has a Return On Assets of 11.38%. This is amongst the best in the industry. ILMN outperforms 91.23% of its industry peers.
- The Return On Equity of ILMN (29.53%) is better than 96.49% of its industry peers.
- ILMN's Return On Invested Capital of 16.40% is amongst the best of the industry. ILMN outperforms 91.23% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.38% | ||
| ROE | 29.53% | ||
| ROIC | 16.4% |
ROA(3y)-22.28%
ROA(5y)-10.63%
ROE(3y)-46.16%
ROE(5y)-23.48%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- ILMN has a better Profit Margin (16.39%) than 89.47% of its industry peers.
- Looking at the Operating Margin, with a value of 20.41%, ILMN belongs to the top of the industry, outperforming 85.96% of the companies in the same industry.
- ILMN's Operating Margin has declined in the last couple of years.
- The Gross Margin of ILMN (66.74%) is better than 87.72% of its industry peers.
- ILMN's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 20.41% | ||
| PM (TTM) | 16.39% | ||
| GM | 66.74% |
OM growth 3YN/A
OM growth 5Y-11.47%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.07%
GM growth 5Y-1.23%
2. Health
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so ILMN is still creating some value.
- Compared to 1 year ago, ILMN has about the same amount of shares outstanding.
- The number of shares outstanding for ILMN has been increased compared to 5 years ago.
- ILMN has a worse debt/assets ratio than last year.
2.2 Solvency
- ILMN has an Altman-Z score of 4.84. This indicates that ILMN is financially healthy and has little risk of bankruptcy at the moment.
- ILMN's Altman-Z score of 4.84 is fine compared to the rest of the industry. ILMN outperforms 77.19% of its industry peers.
- The Debt to FCF ratio of ILMN is 1.99, which is an excellent value as it means it would take ILMN, only 1.99 years of fcf income to pay off all of its debts.
- ILMN has a Debt to FCF ratio of 1.99. This is amongst the best in the industry. ILMN outperforms 87.72% of its industry peers.
- ILMN has a Debt/Equity ratio of 0.42. This is a healthy value indicating a solid balance between debt and equity.
- With a Debt to Equity ratio value of 0.42, ILMN perfoms like the industry average, outperforming 40.35% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.42 | ||
| Debt/FCF | 1.99 | ||
| Altman-Z | 4.84 |
ROIC/WACC1.49
WACC10.98%
2.3 Liquidity
- ILMN has a Current Ratio of 1.43. This is a normal value and indicates that ILMN is financially healthy and should not expect problems in meeting its short term obligations.
- ILMN has a worse Current ratio (1.43) than 77.19% of its industry peers.
- ILMN has a Quick Ratio of 1.12. This is a normal value and indicates that ILMN is financially healthy and should not expect problems in meeting its short term obligations.
- The Quick ratio of ILMN (1.12) is worse than 68.42% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.43 | ||
| Quick Ratio | 1.12 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 152.02% over the past year.
- Measured over the past years, ILMN shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -17.93% on average per year.
- ILMN shows a decrease in Revenue. In the last year, the revenue decreased by -2.32%.
- ILMN shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 4.29% yearly.
EPS 1Y (TTM)152.02%
EPS 3Y-25.65%
EPS 5Y-17.93%
EPS Q2Q%17.54%
Revenue 1Y (TTM)-2.32%
Revenue growth 3Y-1.15%
Revenue growth 5Y4.29%
Sales Q2Q%0.37%
3.2 Future
- ILMN is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 24.95% yearly.
- ILMN is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 3.99% yearly.
EPS Next Y96.03%
EPS Next 2Y44.64%
EPS Next 3Y34.05%
EPS Next 5Y24.95%
Revenue Next Year-0.88%
Revenue Next 2Y0.73%
Revenue Next 3Y2.34%
Revenue Next 5Y3.99%
3.3 Evolution
- The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
- With a Price/Earnings ratio of 35.36, ILMN can be considered very expensive at the moment.
- ILMN's Price/Earnings ratio is a bit cheaper when compared to the industry. ILMN is cheaper than 64.91% of the companies in the same industry.
- ILMN is valuated rather expensively when we compare the Price/Earnings ratio to 27.32, which is the current average of the S&P500 Index.
- With a Price/Forward Earnings ratio of 30.08, ILMN can be considered very expensive at the moment.
- Compared to the rest of the industry, the Price/Forward Earnings ratio of ILMN indicates a somewhat cheap valuation: ILMN is cheaper than 71.93% of the companies listed in the same industry.
- When comparing the Price/Forward Earnings ratio of ILMN to the average of the S&P500 Index (24.30), we can say ILMN is valued slightly more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 35.36 | ||
| Fwd PE | 30.08 |
4.2 Price Multiples
- ILMN's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. ILMN is cheaper than 77.19% of the companies in the same industry.
- 87.72% of the companies in the same industry are more expensive than ILMN, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 23.56 | ||
| EV/EBITDA | 20.68 |
4.3 Compensation for Growth
- The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- ILMN has a very decent profitability rating, which may justify a higher PE ratio.
- A more expensive valuation may be justified as ILMN's earnings are expected to grow with 34.05% in the coming years.
PEG (NY)0.37
PEG (5Y)N/A
EPS Next 2Y44.64%
EPS Next 3Y34.05%
5. Dividend
5.1 Amount
- ILMN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NASDAQ:ILMN (1/22/2026, 10:01:07 AM)
154.19
+1.71 (+1.12%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)10-30 2025-10-30/amc
Earnings (Next)02-05 2026-02-05/amc
Inst Owners104.7%
Inst Owner Change0.5%
Ins Owners0.17%
Ins Owner Change-0.21%
Market Cap23.56B
Revenue(TTM)4.29B
Net Income(TTM)703.00M
Analysts73.33
Price Target132.25 (-14.23%)
Short Float %4.46%
Short Ratio4.02
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)13.9%
Min EPS beat(2)12.52%
Max EPS beat(2)15.27%
EPS beat(4)3
Avg EPS beat(4)5.34%
Min EPS beat(4)-7.76%
Max EPS beat(4)15.27%
EPS beat(8)6
Avg EPS beat(8)97.15%
EPS beat(12)10
Avg EPS beat(12)231.96%
EPS beat(16)13
Avg EPS beat(16)178.01%
Revenue beat(2)0
Avg Revenue beat(2)-0.74%
Min Revenue beat(2)-1.21%
Max Revenue beat(2)-0.28%
Revenue beat(4)0
Avg Revenue beat(4)-0.66%
Min Revenue beat(4)-1.21%
Max Revenue beat(4)-0.18%
Revenue beat(8)3
Avg Revenue beat(8)-0.29%
Revenue beat(12)4
Avg Revenue beat(12)-0.57%
Revenue beat(16)5
Avg Revenue beat(16)-0.78%
PT rev (1m)7.1%
PT rev (3m)16.16%
EPS NQ rev (1m)-0.24%
EPS NQ rev (3m)3.5%
EPS NY rev (1m)-0.01%
EPS NY rev (3m)4.26%
Revenue NQ rev (1m)-0.18%
Revenue NQ rev (3m)0.54%
Revenue NY rev (1m)-0.02%
Revenue NY rev (3m)0.53%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 35.36 | ||
| Fwd PE | 30.08 | ||
| P/S | 5.49 | ||
| P/FCF | 23.56 | ||
| P/OCF | 21 | ||
| P/B | 9.9 | ||
| P/tB | 22.59 | ||
| EV/EBITDA | 20.68 |
EPS(TTM)4.36
EY2.83%
EPS(NY)5.13
Fwd EY3.32%
FCF(TTM)6.54
FCFY4.24%
OCF(TTM)7.34
OCFY4.76%
SpS28.06
BVpS15.58
TBVpS6.83
PEG (NY)0.37
PEG (5Y)N/A
Graham Number39.1
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.38% | ||
| ROE | 29.53% | ||
| ROCE | 20.76% | ||
| ROIC | 16.4% | ||
| ROICexc | 23.54% | ||
| ROICexgc | 43.23% | ||
| OM | 20.41% | ||
| PM (TTM) | 16.39% | ||
| GM | 66.74% | ||
| FCFM | 23.32% |
ROA(3y)-22.28%
ROA(5y)-10.63%
ROE(3y)-46.16%
ROE(5y)-23.48%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5Y-6.48%
ROICexc growth 3YN/A
ROICexc growth 5Y-9.28%
OM growth 3YN/A
OM growth 5Y-11.47%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.07%
GM growth 5Y-1.23%
F-Score7
Asset Turnover0.69
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.42 | ||
| Debt/FCF | 1.99 | ||
| Debt/EBITDA | 0.86 | ||
| Cap/Depr | 44.36% | ||
| Cap/Sales | 2.85% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 97.57% | ||
| Profit Quality | 142.25% | ||
| Current Ratio | 1.43 | ||
| Quick Ratio | 1.12 | ||
| Altman-Z | 4.84 |
F-Score7
WACC10.98%
ROIC/WACC1.49
Cap/Depr(3y)66.6%
Cap/Depr(5y)76.75%
Cap/Sales(3y)5.82%
Cap/Sales(5y)5.58%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)152.02%
EPS 3Y-25.65%
EPS 5Y-17.93%
EPS Q2Q%17.54%
EPS Next Y96.03%
EPS Next 2Y44.64%
EPS Next 3Y34.05%
EPS Next 5Y24.95%
Revenue 1Y (TTM)-2.32%
Revenue growth 3Y-1.15%
Revenue growth 5Y4.29%
Sales Q2Q%0.37%
Revenue Next Year-0.88%
Revenue Next 2Y0.73%
Revenue Next 3Y2.34%
Revenue Next 5Y3.99%
EBIT growth 1Y154.36%
EBIT growth 3YN/A
EBIT growth 5Y-7.67%
EBIT Next Year36.79%
EBIT Next 3Y17.14%
EBIT Next 5Y16.22%
FCF growth 1Y495.24%
FCF growth 3Y28.14%
FCF growth 5Y-3.38%
OCF growth 1Y179.8%
OCF growth 3Y15.37%
OCF growth 5Y-4.45%
ILLUMINA INC / ILMN FAQ
Can you provide the ChartMill fundamental rating for ILLUMINA INC?
ChartMill assigns a fundamental rating of 5 / 10 to ILMN.
Can you provide the valuation status for ILLUMINA INC?
ChartMill assigns a valuation rating of 6 / 10 to ILLUMINA INC (ILMN). This can be considered as Fairly Valued.
How profitable is ILLUMINA INC (ILMN) stock?
ILLUMINA INC (ILMN) has a profitability rating of 7 / 10.
What is the financial health of ILLUMINA INC (ILMN) stock?
The financial health rating of ILLUMINA INC (ILMN) is 5 / 10.
What is the expected EPS growth for ILLUMINA INC (ILMN) stock?
The Earnings per Share (EPS) of ILLUMINA INC (ILMN) is expected to grow by 96.03% in the next year.